Seeking Alpha

Ligand lifts guidance on higher-than-expected Captisol sales

  • Ligand Pharmaceuticals (LGND) rallies 6% premarket.
  • The company is out raising its top- and bottom-line guidance for both Q4 and FY13.
  • Q4 and FY13 revenues now seen at $14-14.5M (versus previous guidance of $11-12M) and $48-48.5M (versus previous guidance of $45-46M), respectively.
  • Q4 and FY13 non-GAAP EPS are now seen at $0.31-0.32 (versus previous guidance of $0.22-0.24) and $0.86-0.87 (versus previous guidance of $0.77-0.79), respectively.
  • LGND cites "higher-than-expected sales of Captisol material." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|